Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directors' Dealings

21st Nov 2008 12:45

RNS Number : 6831I
ABCAM Plc
21 November 2008
 



For immediate release

21 November 2008

ABCAM PLC

("Abcam" or "the Company")

Director Exercise of Options

Cambridge UK, 21 November 2008: Abcam plc announces that on 21 November 2008 David Cleevely exercised options over 40,000 ordinary shares of 1p each in the Company at an exercise price of £1.25 per share and Jonathan Milner exercised options over 40,000 ordinary shares of 1p each in the Company at a price of 62.5 pence per share. Following this transaction David Cleevely has an interest in 3,359,760 ordinary shares representing approximately 9.5% of the Company's issued share capital and Jonathan Milner has an interest in 7,084,960 shares representing approximately 20.0% of the Company's issued share capital.

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities

+ 44 (0) 20 7776 1500

Nominated Adviser - Michael Meade/Nick Westlake

Corporate Broking - James Black

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Mary-Jane Johnson

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in CambridgeUK, with a US office located in CambridgeMassachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 45,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs approximately 180 staff in its three operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSPUGPCGUPRGPG

Related Shares:

ABC.L
FTSE 100 Latest
Value8,809.74
Change53.53